21点评：今年5月，恒瑞医药曾公告显示，该PD-1联用方案上市申请遭到FDA拒绝，原因是生产相关的问题。根据公告，FDA需要全面评估企业在生产场地检查缺陷的完整答复，并且由于部分国家的旅行限制，FDA在审查周期内无法完成该项目必需的生物学研究监测计划临床检查。

The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal ...

The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal ...

GSK plc (LSE/NYSE: GSK) 宣布其用于治疗慢性鼻窦炎伴鼻息肉(CRSwNP)的药物depemokimab在ANCHOR三期临床试验中取得积极成果。根据新闻稿，该试验达到了主要终点，与安慰剂加标准治疗相比，在52周内显著减少了鼻息肉大小和鼻塞程度。 Depemokimab是一种超长效生物制剂，每半年给药一次，在靶向和抑制与鼻息肉生长和阻塞相关的炎症方面显示出了前景。 GSK高级副 ...

Sadeq Ali Quraishi, MD, a former Tufts Medical Center anesthesiologist, has been convicted of attempted sex trafficking of a ...

10月13日， 康方生物 宣布完成新一轮股票配售，成功融资约19.42亿港元。本次融资金额的70%将用于加速 康方生物 自主研发新药在全球范围内的临床开发。 诺和诺德 以其 减肥药 Wegovy闻名于世，正在利用 AI 创新来简化运营并提高效率。 通过在印度（全球最大的糖尿病药物市场之一）进行战略定位， 诺和诺德 预计将通过提高生产能力来满足日益增长的需求。

MSD will provide KEYTRUDA for the Exelixis-sponsored Phase III STELLAR-305 trial. Credit: JeanLucIchard/Shutterstock. US-based biotechnology companies Exelixis and ...

GSK announced positive results from two phase 3 clinical trials evaluating its experimental drug, depemokimab, for chronic rhinosinusitis with nasal polyps affecting 4% of the population.

TI Fluid, which makes fluid systems for the likes of Aston Martin, Porsche and Fiat, said it has received a fifth takeover ...

LONDON, UK I October 14, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results from the phase III clinical trials ANCHOR-1 and ANCHOR-2, ...

The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.

智通财经APP获悉，葛兰素史克(GSK.US)用于治疗一种常见鼻炎的实验性药物在两项后期试验中显示出积极的结果，这促进了这家英国制药商的研发管道。据了解，Depemokimab有助于减少患有慢性鼻窦炎伴鼻息肉患者的鼻塞和息肉大小，葛兰素史克表示，这是 ...